FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus …
WEB3 days ago · RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with pemetrexed and platinum chemotherapy, for the first-line treatment of adult patients with unresectable advanced or metastatic malignant pleural mesothelioma (MPM).
Ten-Year Data for Merck’s KEYTRUDA® (pembrolizumab) …
WEB6 days ago · RAHWAY, N.J., September 15, 2024--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced long-term overall survival (OS) data from the pivotal Phase 3 KEYNOTE-006 ...
Merck wins first FDA approval for Keytruda as a treatment for ...
WEB3 days ago · Merck & Co. Inc. said Wednesday the U.S. Food and Drug Administration has approved its blockbuster cancer drug Keytruda as a treatment for malignant plural mesothelioma, a rare cancer associated ...
FDA approves pembrolizumab for adjuvant treatment
WEBOn November 17, 2021, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) for the adjuvant treatment of patients with renal cell carcinoma (RCC) at intermediate-high...
Merck Receives Positive EU CHMP Opinions for KEYTRUDA® (pembrolizumab …
WEB1 day ago · This news release of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private ...
FDA approves pembrolizumab as adjuvant treatment for non …
WEBOn January 26, 2023, the Food and Drug Administration (FDA) approved pembrolizumab (Keytruda, Merck) for adjuvant treatment following resection and platinum-based chemotherapy for stage IB...
FDA approves pembrolizumab combination for the first-line …
WEBOn October 13,2021, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) in combination with chemotherapy, with or without bevacizumab, for patients with persistent,...
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) as …
WEBDec 3, 2021 · Non-Small Cell Lung Cancer. KEYTRUDA, in combination with pemetrexed and platinum chemotherapy, is indicated for the first-line treatment of patients with metastatic nonsquamous non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations.
Pembrolizumab improves outcomes in high-risk bladder cancer
WEB5 days ago · NCI Press Office. 240-760-6600. Adjuvant pembrolizumab helps people with muscle-invasive bladder cancer remain cancer-free longer than observation alone. Credit: Terese Winslow/National Cancer Institute. Results from a large clinical trial show that treatment with an immunotherapy drug may nearly …
Merck Receives Positive EU CHMP Opinions for KEYTRUDA® (pembrolizumab …
WEB1 day ago · RAHWAY, N.J., September 20, 2024--Merck Receives Positive EU CHMP Opinions for KEYTRUDA® (pembrolizumab) Regimens as Treatment for Patients With Two Gynecologic Cancers
Skip to content